Orladeyo Now Available for Hereditary Angioedema
The oral, once-daily treatment will be shipped to patients with a prescription by specialty pharmacy Optime Care, Inc.
The oral, once-daily treatment will be shipped to patients with a prescription by specialty pharmacy Optime Care, Inc.
Orladeyo works by binding to plasma kallikrein and inhibiting its proteolytic activity.
Lanadelumab was effective for reducing hereditary angioedema attacks at up to 30 weeks of treatment, suggesting the monoclonal antibody is associated with sustained long-term efficacy.
Patients with hereditary angioedema taking berotralstat prophylactically had improved quality of life.
The expanded approval was based on data from the pivotal phase 3 COMPACT study and the COMPACT open-label extension study.
The New Drug Application (NDA) for berotralstat (BCX7353; BioCryst) for the prevention of hereditary angioedema (HAE) attacks has been submitted to the Food and Drug Administration.
This article is part of MPR‘s coverage of the ACAAI 2019 meeting, taking place in Houston, TX. Our staff will report on medical research related to allergies, asthma, and more conducted by experts in the field. Check back regularly for more news from ACAAI 2019. Data from the open-label extension (OLE) portion of the phase…
The oral plasma kallikrein inhibitor, BCX7353, reduced hereditary angioedema attacks during a 24-week treatment period.
Results from a phase 3 trial evaluating BCX7353 (BioCryst), an investigational therapy for hereditary angioedema (HAE), showed that the oral plasma kallikrein inhibitor significantly reduced the rate of HAE attacks, the primary endpoint of the study.
This article is part of MPR‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019. Researchers sought to examine…